Sutton, MS; Rendell, M.; Dandona, P.; Dole, JF; Murphy, K.; Patwardhan, R.; Patel, J.; Freed, M.; Rosiglitazone Clin Trials Study Gr. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes care. 2002, NOV. 25(11):2058-2064.

Rendell, M. Pioglitazone. Drugs. 2006, . 66(14):1879-1880.

Rendell, M. S. Postprandial hyperglycemia: Why do we care about it? What should we do? Drug Development Research. 2006, JUL. 67(7):582-586.

Rendell, M. S. and Jovanovic, L. Targeting postprandial hyperglycemia. Metabolism-Clinical and Experimental. 2006, SEP. 55(9):1263-1281.

Rendell, M. and Gurwitz, D. Metabolic syndrome: A wake-up call. Drug Development Research. 2006, JUL. 67(7):535-538.

Rosenstock, J.; Rendell, M. S.; Gross, J. L.; Fleck, P. R.; Wilson, C. A.; Mekki, Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1c) without causing weight gain or increased hypoglycaemia. Diabetes Obesity & Metabolism. 2009, DEC. 11(12):1145-1152.

Rendell, M. S. Insulin treatment of post-prandial hyperglycemia. Drug Development Research. 2008, MAY. 69(3):124-129.

Rendell, M. Insulin: Moments in history. Drug Development Research. 2008, MAY. 69(3):95-100.

Rosenstock, Julio; Foley, James E.; Rendell, Marc; Landin-Olsson, Mona; Holst, Jens J.; Deacon, Carolyn F.; Rochotte, Erika; Baron, Michelle A. Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance. Diabetes care. 2008, 01. 31(1):30-35.

Wigington, G.; Ngo, B.; Rendell, M. Skin blood flow in diabetic dermopathy. Archives of Dermatology. 2004, OCT. 140(10):1248-1250.